<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990089</url>
  </required_header>
  <id_info>
    <org_study_id>02-0521-001</org_study_id>
    <nct_id>NCT04990089</nct_id>
  </id_info>
  <brief_title>VIVO European Observational Registry</brief_title>
  <official_title>VIVO in a Practical Clinical Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catheter Precision. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catheter Precision. Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, observational registry conducted in Europe and the UK to prospectively review&#xD;
      VIVO in a clinical setting in 125 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>1 day</time_frame>
    <description>The primary effectiveness objective is to assess the types of procedures where VIVO is used to plan and/or guide the ablation procedure or to determine a diagnosis of arrhythmia.&#xD;
Primary Effectiveness endpoint: Summarize the types of procedures where VIVO was utilized in the procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 day</time_frame>
    <description>Primary safety objective is to assess any adverse events related to the device and procedure.&#xD;
Primary Safety endpoint: Summarize the number of adverse events related to VIVO or procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary effectiveness objective is to evaluate the success of the ablation procedure (if performed) at follow- up visits (3, 6 and 12 months).&#xD;
Secondary effectiveness endpoint: Summarize the success of the ablation procedure at each follow up visit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Ventricular Arrythmia</condition>
  <condition>Ventricular Tachycardia</condition>
  <condition>Premature Ventricular Contraction</condition>
  <arm_group>
    <arm_group_label>VIVO</arm_group_label>
    <description>Patients in which VIVO is used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VIVO</intervention_name>
    <description>VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.</description>
    <arm_group_label>VIVO</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients experiencing ventricular tachycardia (VT) or premature ventricular contractions&#xD;
        (PVC) and being considered for or have a scheduled a ventricular ablation procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must at least 18 years of age Patients who have signed an IRB/EC approved&#xD;
             patient informed consent and applicable patient privacy protection authorization per&#xD;
             local law&#xD;
&#xD;
          -  Patients who have previously had contrast cardiac imaging or will have cardiac imaging&#xD;
             ordered per standard of care&#xD;
&#xD;
          -  Patients will be selected without regard to gender.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Patients that are unable to receive contrast cardiac imaging (MR or CT)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Ng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glenfield University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Missiaen Huck</last_name>
    <phone>973-691-2000</phone>
    <email>mhuck@catheterprecision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Prescott</last_name>
    <phone>973-691-2000</phone>
    <email>dprescott@catheterprecision.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>NO IPD is to be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

